Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: A review;Laktobasil Ve Estriol Kombinasyonunun Bozulmuş Vajina Ekosisteminin Tedavisinde Kullanımı: Bir Derleme

Journal of the Turkish German Gynecology Association

Volumn 12, Issue 4, 2011, Pages 239-246

  Ünlü, Cihat ^a   Donders, Gilbert ^b  

^a ACIBADEM UNIVERSITY   (Turkey)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Abnormal vaginal flora; Estriol; Lactobacillus acidophilus; Recurrence prevention; Restoration of vaginal ecosystem; Vaginal atrophy

Indexed keywords

ANTIINFECTIVE AGENT; CLINDAMYCIN; ESTRADIOL; ESTRIOL; ESTROGEN DERIVATIVE; GYNOFLOR; HYDROGEN PEROXIDE; LACTIC ACID; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; SUPPOSITORY BASE; UNCLASSIFIED DRUG;

CELL ADHESION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; ENDOMETRIUM; EPITHELIUM CELL; FEMALE; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; LACTOBACILLUS ACIDOPHILUS; LONG TERM CARE; LOW DRUG DOSE; MICROFLORA; POSTMENOPAUSE; PREGNANCY; PREMENOPAUSE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN REDNESS; VAGINA ATROPHY; VAGINA DISEASE; VAGINITIS;

EID: 82555201419     PISSN: 13090399     EISSN: 13090380     Source Type: Journal    
DOI: 10.5152/jtgga.2011.57     Document Type: Review

References (49)

1. Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 1990; 12: 856-72. [CrossRef]
2. Head KA. Estriol: safety and efficacy. Altern Med Rev 1998; 3: 101-13.
3. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010; 13: 509-22. [CrossRef]
4. Witkin SS, Linhares IM, Giraldo P. Bacterial flora of the female genital tract: function and immune regulation. Best Pract Res Clin Obstet Gynaecol 2007; 21: 347-54. [CrossRef]
5. Lamont RF, Sobel JD, Akins RA, Hassan SS, Chaiworapongsa T, Kusanovic JP, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 2011; 118: 533-49. [CrossRef]
6. Reid G, Younes JA, van der Mei HC, Gloor GB, Knight R, Busscher HJ. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol 2011; 9: 27-38. [CrossRef]
7. Eschenbach DA, Davick PR, Williams BL, Klebanoff SJ, Young-Smith K, Critchlow CM, et al. Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1989; 27: 251-6. [CrossRef]
8. Barbes C, Boris S. Potential role of lactobacilli as prophylactic agents against genital pathogens. AIDS Patient Care STDS 1999; 13: 747-51. [CrossRef]
9. Fredricks DN. Molecular methods to describe the spectrum and dynamics of the vaginal microbiota. Anaerobe 2011; 17: 191-5. [CrossRef]
10. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005; 353: 1899-911. [CrossRef]
11. McGroarty JA. Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med Microbiol 1993; 6: 251-64. [CrossRef]
12. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009; 12: 91-105. [CrossRef]
13. Simon JA. Vulvovaginal atrophy: new and upcoming approaches. Menopause 2009; 16: 5-7. [CrossRef]
14. Donders G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet Gynecol Surv 2010; 65: 462-73. [CrossRef]
15. Sobel JD. Bacterial vaginosis. Annu Rev Med 2000; 51: 349-56.
16. Schöni M, Graf F, Meier B. Behandlung von Vaginalstörungen mit Döderlein-Keimen. SAZ 1988; 126: 139-42. [CrossRef]
17. Witkin SS, Alvi S, Bongiovanni AM, Linhares IM, Ledger WJ. Lactic acid stimulates interleukin-23 production by peripheral blood mononuclear cells exposed to bacterial lipopolysaccharide. FEMS Immunol Med Microbiol 2011; 61: 153-8. [CrossRef]
18. Kanne B, Beyerle-Müller HL, Patz B, Wackerle L. Die antibiotische Aktivität der Döderleinflora zur lokalen Behandlung vaginaler Infektionen mit lebensfähigen Döderleinkeimen und Estriol. Jatros Gynäkologie 1986; 2: 3-28.
19. Boris S, Barbes C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes Infect 2000; 2: 543-6. [CrossRef]
20. Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G. The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG 2005; 112: 234-40. [CrossRef]
21. Witkin SS, Linhares IM, Giraldo P, Ledger WJ. An altered immunity hypothesis for the development of symptomatic bacterial vaginosis. Clin Infect Dis 2007; 44: 554-7. [CrossRef]
22. McMillan A, Dell M, Zellar MP, Cribby S, Martz S, Hong E, et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf B Biointerfaces 2011; 86: 58-64. [CrossRef]
23. Vooijs GP, Geurts TBP. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol 1995; 62: 101-6. [CrossRef]
24. Englund DE, Elamsson KB, Johansson EDB. Bioavailability of oestriol. Acta Endocrinol (Copenh) 1982; 99: 136-40.
25. Keller PJ, Riedmann R, Fischer M. Estrone, estradiol and estriol content after intravaginal application of estriol in postmenopause. Gynäkol Rundsch 1980; 20: 77-9.
26. Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008; 13: 222-31. [CrossRef]
27. Reid G, Bruce AW. Selection of lactobacillus strains for urogenital probiotic applications. J Infect Dis 2001; 183: 77-80. [CrossRef]
28. Kaiser RR, Michael-Hepp J, Weber W, Graf F, Lauritzen C. Absorption of estriol from vaginal tablets after single and repeated application in healthy, postmenopausal women. Therapiewoche 2000.
29. Abad CL, Safdar N. The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review. J Chemother 2009; 21: 243-52.
30. Barrons R, Tassone D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 2008; 30: 453-68. [CrossRef]
31. Lauritzen C, Graf F, Mucha M. Restoration of the physiological vaginal environment with Doederlein bacteria and estriol. Frauenarzt 1984; 4.
32. Horvath B, Hadarits F, Szabo L, Serenyi P, Godo G. Probiotic treatment of vaginal infections. A prospective study of the treatment of 144 patient with Gynoflor vaginal tablets. Journal of Hungarian Association for Obstetrics and Gynecology [Magyar Nöorv. Labj] 2004; 67: 85-91.
33. Melczer Z, Langmar Z, Paulin F. Experience with local ecotherapy in the treatment of bacterial vaginosis in pregnant and non-pregnant women. Journal of Hungarian Association for Obstetrics and Gynecology [Magyar Nöorv. Labj] 2002; 65: 319-23.
34. Grishchenko OV, Dudko VL, Lakchno IV, Storchak AV. Gynoflor application in preoperative preparation complex for women suffering from colpoptosis. Women Reproductive Health (WHR) 2007; 2.
35. Tatarchuk TF, Zacharenko NF, Kosey NV, Suhorebraya EI. Function of vaginal ecosystem in postoperative complications prophylaxis. "Women Reproductive Health" (WHR) 2006; #4.
36. Parent D, Bossens M, Bayot D, Kirkpatrick C, Graf F, Wilkinson FE, et al. Therapy of bacterial vaginosis using exogenously-applied Lactobacilli acidophili and a low dose of estriol. Arzneimittelforschung 1996; 46: 68-73.
37. Amsel R, Totten PA, Spiegel CA, Chen KCS, Eschenbach DA, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiological associations. Am J Med 1983; 74: 14-22. [CrossRef]
38. Donders GG, Van Bulck B, Van de Walle P, Kaiser RR, Pohlig G, Gonser S, et al. Effect of Lyophilized Lactobacilli and 0.03 mg Estriol (Gynoflor(R) on Vaginitis and Vaginosis with Disrupted Vaginal Microflora: A Multicenter, Randomized, Single-Blind, Active-Controlled Pilot Study. Gynecol Obstet Invest 2010; 70: 264-72. [CrossRef]
39. Unzeitig V, Al Awad H. New options of stabilization of disturbed vaginal environment balance. Prakticka Gynekologia 2006; 10: 170-3.
40. Larsson PG, Stray-Pedersen B, Ryttig KR, Larsen S. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health 2008; 8: 3. [CrossRef]
41. Larsson PG, Brandsborg E, Forsum U, Pendharkar S, Andersen KK, Nasic S, et al. Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infect Dis 2011; 11: 223. [CrossRef]
42. Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010; 26: 404-12. [CrossRef]
43. Pfeiler G, Glatz C, Königsberg R, Geisendorfer T, Fink-Retter A, Kubista E, et al. Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric 2011; 14: 339-44. [CrossRef]
44. Kanne B, Patz B, Wackerle L. Lokale Behandlung vaginaler Infektionen mit Döderlein-Keimen und Estriol im Klimakterium und Senium. Frauenarzt 1986; 3: 35-40.
45. Kanne B, Jenny J. Local administration of low-dose estriol and vital Lactobacillus acidophilus in postmenopause. Gynäkol Rundsch 1991; 31: 7-13. [CrossRef]
46. Feiks A, Grünberger W. Therapie der atrophen Kolpitis-Ist eine Reduktion der Östrogendosis bei lokaler Anwendung möglich? Gynäkol Rundsch 1991; 31: 268-71. [CrossRef]
47. Hengst P, Uhlig B, Bollmann R, Kokott T. Uses of vaginal pH measurement for prevention of premature labor. Results of a prospective study. Z Geburtshilfe Perinatol 1992; 196: 238-41.
48. Hoyme UB, Grosch A, Roemer VM, Saling E. Erste Resultate der Erfurter Frühgeburten-Vermeidungs-Aktion. Zeitschrift für Geburtshilfe & Neonatologie 1998; 6: 247-50.
49. Hoyme UB, Saling E. Efficient prematurity prevention is possible by pH-self measurement and immediate therapy of threatening ascending infection. Eur J Obstet Gynecol Reprod Biol 2004; 115: 148-53. [CrossRef]